ACE and COVID-19: A total of 210 patients with CHD were analyzed (mean age 21.6 months; 59.5% female). COVID-19 prevalence was significantly higher than in the general population (p=0.00012), though severe cases were rare, with few ICU admissions and one death. No association was found between ARB/ ACE inhibitor use and infection risk.